BioFocus Screening Targets for Almirall | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioFocus will use its screening technologies and compound collections to find new hit compounds against key targets of interest for Barcelona, Spain-based pharmaceutical firm Almirall under a new agreement announced today.

Almirall said that BioFocus will help it find new hit compounds against key targets as possible treatments for respiratory and inflammatory conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.